AstraZeneca’s COPD therapy gets US FDA approval
UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic lung disease, COPD.
The FDA has okayed its Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) as long-term, maintenance treatment for COPD, the company said in a statement.
Chief Medical Officer Sean Bohen, said: “With the approval of Bevespi Aerosphere we are pleased to provide patients with the first Lama/ Laba in a pressurised metered-dose inhaler, delivered using our unique formulation technology. Lama/ Labas are emerging as a preferred treatment option for many COPD patients. This class aims to provide maximum bronchodilation, which enables patients to breathe better and may help them be more active.”
COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness, AstraZeneca said.
It affects an estimated 329 million people worldwide and is predicted to be the third leading cause of death by 2030.
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is …